ym 529 has been researched along with Osteoporosis, Postmenopausal in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ishida, K; Kimura, T; Kobayashi, M; Komura, N; Miyamoto, M; Sawada, K; Shimizu, A; Shimura, K; Yamamoto, M; Yoshimura, A | 1 |
| Fukunaga, M; Hagino, H; Miyazaki, T; Mori, S; Nakamura, T; Ohta, H; Orimo, H; Shiraki, M; Soen, S; Sone, T; Sugimoto, T; Taguchi, A; Tanaka, S; Tsukiyama, M; Uemura, Y | 1 |
| Chikuda, H; Inoue, M; Kaneko, T; Okamura, K; Okura, C; Suto, T; Tachibana, M; Tamura, Y; Yonemoto, Y | 1 |
| Morio, Y; Tanishima, S | 1 |
| Igase, M; Kohara, K; Miki, T; Ochi, M; Ohara, M; Okada, Y; Tabara, Y; Takita, R | 1 |
| Kawabata, K; Mori, H; Tanaka, M | 1 |
| Ebina, K; Hashimoto, J; Hirao, M; Kaneshiro, S; Noguchi, T; Yoshikawa, H; Yukioka, M | 1 |
| Fukunaga, M; Hagino, H; Matsumoto, T; Morii, H; Nakamura, T; Nakano, T; Ohashi, Y; Shiraki, M; Takaoka, K | 1 |
| Hagino, H; Itabashi, A; Matsumoto, T; Minamide, T; Mizunuma, H; Morii, H; Nakamura, T; Nishizawa, Y; Ohashi, Y; Shiraki, M; Sone, T; Taketani, Y | 1 |
| Fukunaga, M; Ito, M; Sone, T | 1 |
| Hagino, H | 1 |
| Fukunaga, M; Hagino, H; Ito, M; Matsumoto, T; Mizunuma, H; Nakamura, T; Nishizawa, Y; Ohashi, Y; Okazaki, R; Shiraki, M; Sone, T | 1 |
| Fukunaga, M; Hagino, H; Matsumoto, T; Nakamura, T; Nakano, T; Ohashi, Y; Shiraki, M; Takaoka, K | 1 |
| Okamoto, K; Okimoto, N; Sakai, A; Yoshioka, T | 1 |
| Chatani, Y | 1 |
| Takata, S | 1 |
4 review(s) available for ym 529 and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
A review of minodronic acid hydrate for the treatment of osteoporosis.
Topics: Aged; Aged, 80 and over; Aging; Biomarkers; Bone Density; Bone Density Conservation Agents; Delayed-Action Preparations; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Spinal Fractures | 2013 |
[Minodronic acid- its clinical efficacy and prospects for once-a-month dosing regimen].
Topics: Administration, Oral; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis, Postmenopausal; Patient Compliance; Quality of Life; Risk; Spinal Fractures; Time Factors | 2011 |
[Minodronic acid hydrate as a new therapeutic agent for osteoporosis].
Topics: Animals; Bone Density; Bone Resorption; Clinical Trials, Phase II as Topic; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Polyisoprenyl Phosphates; Rats; Sesquiterpenes | 2005 |
[New bone density conservation agents for osteoporosis under research and development: Minodronic acid].
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Drug Design; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Research | 2007 |
8 trial(s) available for ym 529 and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Japan; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality of Life; Raloxifene Hydrochloride; Treatment Outcome | 2020 |
Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Ankle Brachial Index; Atherosclerosis; Bone Density Conservation Agents; Brachial Artery; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Prospective Studies; Pulsatile Flow; Treatment Outcome | 2014 |
Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Biomarkers; Body Height; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Spinal Fractures; Treatment Outcome | 2009 |
A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome | 2009 |
Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Algorithms; Biomarkers; Body Mass Index; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Femur; Hip; Humans; Imidazoles; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Time Factors | 2010 |
Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Hip Joint; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Treatment Outcome | 2012 |
Three years of treatment with minodronate in patients with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Resorption; Calcium, Dietary; Cholecalciferol; Cohort Studies; Combined Modality Therapy; Dietary Supplements; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Incidence; Lumbar Vertebrae; Middle Aged; Osteogenesis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Time Factors | 2012 |
A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients.
Topics: Aged; Alendronate; Back Pain; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Collagen Type I; Diphosphonates; Drug Administration Schedule; Female; Gastrointestinal Tract; Humans; Imidazoles; Osteoporosis, Postmenopausal; Pain Measurement; Peptides; Surveys and Questionnaires | 2013 |
4 other study(ies) available for ym 529 and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug Substitution; Female; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Treatment Outcome | 2020 |
Short-term daily teriparatide in patients with rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Teriparatide | 2018 |
Attenuation of Antiresorptive Action in Withdrawal of Minodronic Acid for Three Months After Treatment for Twelve Months in Ovariectomized Rats.
Topics: Absorptiometry, Photon; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Inbred F344 | 2015 |
Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Drug Substitution; Female; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Patient Preference; Prospective Studies; Risedronic Acid | 2016 |